ArticleBMC medical imaging2025
A mixture of experts (MoE) model to improve AI-based computational pathology prediction performance under variable levels of image blur.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Large Language Models for Patient Education in Cardiovascular Imaging: Prospective Observational Comparative Study.JMIR formative research · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAI-based models for analysis of histopathology whole slide images (WSIs) are now common. However, image quality, particularly unsharp areas of WSIs, impacts model performance. In this study we investigate the impact of blur on deep learning models for WSI analysis. We propose a mixture of experts (MoE) strategy that mitigates the impact of unsharp areas in WSIs on classification performance by combining predictions from multiple expert models trained on data with varying levels of blur.
methodsThe study included hematoxylin and eosin (H&E) stained WSIs from 2093 breast cancer patients. Classification of histological grades 1 and 3 was used as a primary benchmarking case, and prediction of immunohistochemistry (IHC) markers (ER, PR, HER2) from H&E as a secondary case. The proposed MoE strategy to improve robustness against blur was evaluated in both a deep CNN model (CNN_CLAM and MoE-CNN_CLAM) and a Vision Transformer-based histopathology foundation model (UNI_CLAM and MoE-UNI_CLAM). For each architecture, a baseline model was trained on sharp images, and multiple expert models were trained on tiles with added Gaussian blur at different levels. Model performance (area under the ROC curve) was evaluated under multiple levels of uniform blur, as well as in several simulated scenarios with a mixture of blur levels within the WSIs.
resultsBaseline model performance degraded with increasing blur for all evaluated architectures. Individual expert models trained on data with simulated Gaussian blur performed better on unsharp images compared to baseline models. The proposed MoE consistently outperformed its respective baseline models in simulation scenarios with various degrees of blur within WSIs. MoE-CNN_CLAM outperformed the baseline CNN_CLAM under moderate (AUC: 0.868 vs. 0.702) and mixed blur conditions (AUC: 0.890 vs. 0.875). MoE-UNI_CLAM outperformed the baseline UNI_CLAM model in both moderate (AUC: 0.950 vs. 0.928) and mixed blur conditions (AUC: 0.944 vs. 0.931).
conclusionsUnsharp image areas are common in WSIs and impact prediction performance. The proposed MoE strategy provided equal or substantially improved prediction performance under all evaluated test scenarios. The proposed methodology has the potential to increase quality and reliability of AI-based pathology models in both research and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.